Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.FDA to review Genta drug in leukemia indication
The company is seeking approval for the use of Genasense plus fludarabine and cyclophosphamide for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia (CLL). “This
The company is seeking approval for the use of Genasense plus fludarabine and cyclophosphamide for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia (CLL). “This
Rituxan has been specifically approved to be used in combination with methotrexate to reduce signs and symptoms in adult patients with moderately-to-severely active rheumatoid arthritis (RA) who have
RxKinetix recently completed a phase II trial of RK-0202 in patients with head and neck cancer. The trial successfully demonstrated the drug’s efficacy, with patients receiving RK-0202 having
In the collaboration, Roche will elect new target molecules against which MorphoSys will generate antibodies using its proprietary HuCAL Gold technology. The companies will collaborate on two new
The Delcath system delivers high-dose chemotherapy directly to the liver via the hepatic artery. As blood exits the liver, special filters trap the chemotherapy, protecting the rest of
The study suggests that a delayed release of the drugs active ingredient, methylphenidate, does not produce the feelings of euphoria associated with abusable drugs. Study participants taking therapeutic
Priority review is granted to products that are considered to be potentially significant therapeutic advancements over existing approved therapies in the treatment, diagnosis or prevention of a disease.
Sanofi says Apidra (insulin glulisine rDNA origin injection) is to be used in regimens that include a longer-acting insulin or basal insulin analog such as Lantus. The company
The company also announced it has closed enrollment of further patients into the study and, based on the study’s 26 week dosing period, reaffirmed its prior forecast that
Based on the clinical data, the company plans to initiate a new phase I/II trial of Atiprimod in carcinoid cancer patients with advanced tumors that it plans to